SSG
HZNP

Summit Securities Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Summit Securities Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-123,600
Closed -$14.3M – 987
2023
Q3 		$14.3M Sell
123,600
-40,400
-25% -$4.34M 1.47% 14
2023
Q2 		$16.9M Buy
164,000
+85,200
+108% +$8.99M 2.2% 10
2023
Q1 		$8.6M Sell
78,800
-71,700
-48% -$7.93M 0.71% 27
2022
Q4 		$17.1M Buy
+150,500
New +$12.5M 0.64% 36

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Summit Securities Group's HZNP Position: Q4 2023 in Review

Summit Securities Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 16,523 shares — an estimated $1.91M sold.

Summit Securities Group first reported a position in HZNP in Q3 2013 and held it in 2 quarters. The position peaked at $1.91M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Summit Securities Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Summit Securities Group sold 16,523 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.91M.
  • Summit Securities Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 2 quarters.
  • Summit Securities Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.91M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Summit Securities Group's 13F filing for Q4 2023, filed 14 Feb 2024.